Department of Pediatrics and Center for Bioethics, University of Minnesota, Minneapolis.
Haslinger Family Pediatric Palliative Care Center, Akron Children's Hospital, Akron, Ohio.
JAMA Netw Open. 2022 Jul 1;5(7):e2220696. doi: 10.1001/jamanetworkopen.2022.20696.
The effect of pediatric advance care planning (pACP) on the sustainability of end-of-life treatment preference congruence between adolescents with cancer and their families has not been examined.
To evaluate the longitudinal efficacy of the Family-Centered Advance Care Planning for Teens with Cancer (FACE-TC) intervention to sustain adolescent-family congruence about end-of-life treatment preferences.
DESIGN, SETTING, AND PARTICIPANTS: This multisite, assessor-blinded, randomized clinical trial enrolled adolescents with cancer (aged 14-21 years) and their family members from 4 pediatric hospitals between July 16, 2016, and April 30, 2019. Participants were randomized 2:1 to FACE-TC (intervention group) or treatment as usual (control group) and underwent 5 follow-up visits over an 18-month postintervention period. Intention-to-treat analyses were conducted from March 9, 2021, to April 14, 2022.
Adolescent-family dyads randomized to the FACE-TC group received 3 weekly 60-minute sessions consisting of the discussion and/or completion of the Lyon Family-Centered Advance Care Planning Survey (session 1), Respecting Choices Next Steps pACP conversation (session 2), and Five Wishes advance directive (session 3). Dyads in the control group received treatment as usual. Both groups received pACP information.
Congruence was measured by completion of the Statement of Treatment Preferences (a document that discusses 4 hypothetical clinical situations and treatment choices for each scenario: continue all treatments, stop all efforts to keep me alive, or unsure) after session 2 (time 1) and at 3 months (time 2), 6 months (time 3), 12 months (time 4), and 18 months (time 5) after intervention. The influence of FACE-TC on the trajectory of congruence over time was measured by longitudinal latent class analysis.
A total of 252 participants (126 adolescent-family dyads) were randomized. Adolescents (mean [SD] age, 17 [1.9] years) and family members (mean [SD] age, 46 [8.3] years) were predominantly female (72 [57%] and 104 [83%]) and White individuals (100 [79%] and 103 [82%]). There was an 83% (104 of 126) retention at the 18-month assessment. Two latent classes of congruence over time were identified: high-congruence latent class (69 of 116 [60%]) and low-congruence latent class (47 of 116 [41%]). The dyads in the FACE-TC group had a 3-fold odds of being in the high-congruence latent class (odds ratio [OR], 3.22; 95% CI, 1.09-9.57) compared with the control group. Statistically significant differences existed at 12 months (β [SE] = 1.17 [0.55]; P = .03]) but not at 18 months (OR, 2.08; 95% CI, 0.92-4.69). In the high-congruence latent class, good agreement (agreement on 2 or 3 of 4 situations) increased over 12 months. White adolescents and families had significantly greater odds of congruence than a small population of American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, or multiracial adolescents and families (OR, 3.97; 95% CI, 1.07-14.69).
Results of this trial showed that, for those who received the FACE-TC intervention, the families' knowledge of their adolescents' end-of-life treatment preferences was sustained for 1 year, suggesting yearly follow-up sessions. Race and ethnicity-based differences in the sustainability of this knowledge reflect a difference in the effect of the intervention and require further study.
ClinicalTrials.gov Identifier: NCT02693665.
重要性:儿科预先医疗照护计划(pACP)对青少年癌症患者及其家庭的临终治疗偏好一致性的可持续性的影响尚未被检验。
目的:评估“青少年癌症家庭为中心的预先医疗照护计划(FACE-TC)”干预的纵向疗效,以维持青少年-家庭在临终治疗偏好上的一致性。
设计、地点和参与者:这是一项多中心、评估者盲法、随机临床试验,招募了来自 4 家儿科医院的年龄在 14-21 岁的青少年癌症患者(n=126)及其家庭成员。参与者以 2:1 的比例随机分为 FACE-TC 组(干预组)或常规治疗组(对照组),并在 18 个月的干预后进行了 5 次随访。意向治疗分析于 2021 年 3 月 9 日至 2022 年 4 月 14 日进行。
暴露:随机分配到 FACE-TC 组的青少年-家庭对接受 3 次每周 60 分钟的会议,包括讨论和/或完成里昂家庭为中心的预先医疗照护计划调查(第 1 次会议)、尊重选择下一步的 pACP 对话(第 2 次会议)和五愿望预先指示(第 3 次会议)。对照组的双元组接受常规治疗。两组都接受了 pACP 信息。
主要结果和测量:在第 2 次会议(时间 1)后和 3 个月(时间 2)、6 个月(时间 3)、12 个月(时间 4)和 18 个月(时间 5)时,通过完成治疗偏好声明(一份讨论 4 种假设临床情况和每种情况的治疗选择的文件:继续所有治疗、停止所有维持生命的努力,或不确定)来衡量一致性。通过纵向潜在类别分析来衡量 FACE-TC 对时间一致性轨迹的影响。
结果:共有 252 名参与者(126 对青少年-家庭)被随机分配。青少年(平均[标准差]年龄,17[1.9]岁)和家庭成员(平均[标准差]年龄,46[8.3]岁)主要为女性(72[57%]和 104[83%])和白人(100[79%]和 103[82%])。18 个月评估时的保留率为 83%(104 名中的 126 名)。确定了两种时间一致性的潜在类别:高一致性潜在类别(69 名中的 116 名[60%])和低一致性潜在类别(47 名中的 116 名[41%])。与对照组相比,FACE-TC 组的双元更有可能处于高一致性潜在类别(优势比[OR],3.22;95%置信区间[CI],1.09-9.57)。在 12 个月时存在统计学显著差异(β[SE],1.17[0.55];P=0.03),但在 18 个月时没有(OR,2.08;95%CI,0.92-4.69)。在高一致性潜在类别中,良好的一致性(在 4 种情况中的 2 种或 3 种情况下达成一致)在 12 个月内增加。白种人青少年和家庭比美洲印第安人或阿拉斯加原住民、亚洲人、黑人和非洲裔美国人、西班牙裔或拉丁裔、或多种族青少年和家庭有更高的一致性可能性(OR,3.97;95%CI,1.07-14.69)。
结论和相关性:这项试验的结果表明,对于那些接受 FACE-TC 干预的人来说,家庭对青少年临终治疗偏好的了解在 1 年内得到了维持,这表明需要每年进行随访。基于种族和族裔的这种知识的可持续性的差异反映了干预效果的差异,需要进一步研究。
试验注册:ClinicalTrials.gov 标识符:NCT02693665。